Enhertu is a treatment for adult patients with unresectable or metastatic HER2 low breast cancer who have previously received chemotherapy. It was approved for use on the NHS in Scotland in December 2023 but has not been approved in England and Wales due to concerns about cost effectiveness. Clinical trial evidence shows that Enhertu increases overall survival by 6.4 months. Negotiations between NICE, NHS England, and the manufacturers have been ongoing since July to make Enhertu available to around 1000 women who would benefit from it. The drug is available in 18 other European countries.
Source link
Does NICE’s “severity modifier” for assessing diseases need to change?
